Latest Breaking News On - Ares genetics - Page 5 : comparemela.com

CORRECTION – OpGen Reports Fourth Quarter and Full Year

ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the.

Oliver schachtCuretis gmbAlbert weberGene panelOpgen investor press contactEdison groupEuropean investment bankInternational numberExchange commissionSecurities exchangeTechnology platformOpgen incFoundation for innovative new diagnosticsFull yearChief financial officerBeijing clear biotech

CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Albert weberCuretis gmbOliver schachtGene panelOpgen investor press contactEdison groupEuropean investment bankSecurities exchangeTechnology platformExchange commissionInternational numberOpgen incFoundation for innovative new diagnosticsFull yearChief financial officerBeijing clear biotech

CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Oliver schachtOliver schachtpresidentCuretis gmbAlbert weberExchange commissionInternational numberTechnology platformFoundation for innovative new diagnosticsGene panelOpgen investor press contactAlyssa factoredison groupEuropean investment bankSecurities exchangeOpgen incFull yearChief financial officer

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Curetis gmbAlbert weberOliver schachtEuropean investment bankInternational numberExchange commissionSecurities exchangeTechnology platformOpgen incFoundation for innovative new diagnosticsGene panelOpgen investor press contactEdison groupFull yearChief financial officerBeijing clear biotech

OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Total revenue for 2022 was approximately $2.6 millionBalance sheet strengthened by recently closed public offering with gross proceeds of $7.5 millionConference call to be held March. | March 29, 2023

Curetis gmbOliver schachtAlbert weberGene panelInternational numberFoundation for innovative new diagnosticsEuropean investment bankSecurities exchangeOpgen investor press contactTechnology platformOpgen incExchange commissionEdison groupFull yearChief financial officerBeijing clear biotech